The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund donanemab - the ...
Donanemab works by removing a sticky protein called beta-amyloid from the brain that is believed to cause Alzheimer's disease, and in the trials ...
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's disease, ...